Innovent bio (01801.HK) announced a recent collaboration with Wecomput to jointly promote the construction of the Innovent Bio National Qingyuan Computing Platform to accelerate the drug development process. It is expected to construct an efficient, easy-to-use, digital, intelligent, and automated one-stop AI drug development platform to reduce the cost of AI landing and experimental costs, shorten the drug development cycle, and improve the success rate of research and development, bringing more innovative drugs and treatment solutions to patients.
信達生物(01801.HK)與唯信計算達成AI藥物研發平台建設合作
Innovent Bio (01801.HK) has reached a cooperation with Insilico Medicine to establish an AI drug R&D platform.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.